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Abstract 
 
Colorectal Cancer is an aggressive disease that claims the lives of 
both men and women every year. It is the second leading cause of 
cancer-related death in the U.S. The overwhelming mortality rate it 
amasses begs for the discovery of alternative forms of treatment. 
The nature of cancer requires immunotherapeutic approach that is 
tumor specific in nature.  Adoptive T-cell therapy is an alternative 
that satisfies these conditions. Guanylyl Cyclase C is a receptor 
found on the luminal side of the gut that is tissue-specific for the 
intestinal epithelium. Further, its expression is maintained 
throughout colorectal tumorigenesis making in an excellent marker 
of metastatic disease. By employing the use of chimeric antigen 
receptors we have created twelve different CAR’s containing 
GCC-specificity which we will use to target tumors expressing 
Guanyl Cyclase C. We hypothesize that these new CAR’s will 
recognize GCC and induce T cell effector responses. 
 
 
 
 
 
 
 
 
 
 
 
 
 Colon Cancer is an aggressive form of cancer that develops in the 
rectum. Colorectal cancer is the fourth most commonly diagnosed 
cancer and the second leading cause of cancer death in both men and 
women combined within the United States. It is estimated that in 2013 
over 50,000 people will die from colorectal cancer. As colorectal cancer 
progresses it becomes metastatic and travels to the lymph nodes and 
various parts of the body. The abysmal death rate in regards to colorectal 
cancer begs for alternative forms of cancer treatment.  
 Adoptive T-Cell therapy is a form of cancer treatment that can 
prove to be very successful. Guanylyl Cylclase C is a gene that codes for 
a protein found in the intestines and cancers arising from the intestine. 
Guanylyl Cyclase C has limited expression in extra-intestinal tissues 
making it an ideal marker for the detection of colorectal cancer 
metastasis in non-intestinal tissues. Recently, we have engineered T cells 
to express GCC specific chimeric antigen receptors in the hope that they 
will attack GCC expressing tumors.  
  
                
 
Figure #1: pMA plasmid containing 5F9. 
 Our research began with the use of circular plasmid entitled pMA. 
The pMA contained a CAR sequence with an antibody sequence derived 
from the 5F9 antibody. 5F9 is a single chain fv that recognizes human 
GCC. A digestion reaction was performed in order to remove the 5F9 
antibody sequence from the CAR pMA plasmid.  
                       
Figure 2: Digestion reaction containing 5F9 & pMA CAR 
 After completing the digestion, a gel extraction was performed to 
remove the PMA CAR from within the gel itself. After isolating the 
CAR containing pma plasmid GeneArt assembly was used to connect 
individual antibodies to the CAR pMA construct. There were twelve 
antibody sequences used to create twelve new CARS. The antibody 
sequences used for the benefit of this experiment are Abx012, Abx020, 
Abx106, Abx198, Abx221, Abx229, Abx338, Abx393, 6H8, 8C2, 
10C10 and 10D3. These antibodies were chosen due to their capabilities 
to recognize human GCC with hopes that at least some would be cross 
reactive for mouse GCC. Seeing as any results obtained would be done 
from a mouse model, the outcome, if favorable, would need to be 
recreated using a human model.  
   
Next, a transformation was preformed inserting the GeneArt reactions 
into bacteria. This allowed the assembled CAR pMA plasmids to get 
into the bacteria. This was made possible by heat shocking the bacteria 
cells. Heat shocking allows for the mild disruption of the cell which 
permits the DNA to enter. The bacteria was then plated out on agarose 
Figure 3: pMA plasmid containing new antibody sequence 
(outlined in red).  
plates for an overnight incubation. Following incubation, colonies were  
picked and grown in order to test for positive insertions.           
 
 Figure 4: Model depicting a   transformation 
reaction. 
  
 After identifying positive clones, 10ML cultures of the cells were 
grown and placed through the plasmid purification process. Next, the 
purified plasmids were sent out for sequencing to confirm correct 
assembly of the new CARs. Once the plasmids were confirmed to be 
correct, the CARs were then digested out of the pMA plasmid. This was 
done with the help of two enzymes entitled XhoI and EcoRI. These 
enzymes used were chosen specifically because they can be found 
Figure 5: PCR screen of clones 
within the new retroviral plasmid that would be used to further the 
experiments. The use of these enzymes would ensure a smooth transition 
of the various CARS from one plasmid to the other.  
  
 
 
Figure #6: pMA plasmid containing XhoI & EcoRI sites.  
  
 A separate digestion reaction was competed in order to disrupt 
pMIG, our retroviral plasmid. This disruption allowed for the integration 
of the CAR  DNA into the retroviral plasmid. Next, using a ligation 
reaction the various CAR’s were attached to the pMIG plasmid. 
Following the ligation, bacteria was transformed with the ligation 
reactions and plated out on agarose plates.  Colonies were then grown; 
Figure 7: pMA CAR digestion 
PCR screened to identify positives, and sequenced to confirm correct 
insertion into pMIG before proceeding to the next step.  
 Next, we made retrovirus from the CAR-pMIG plasmids. In order 
to achieve this, the retroviral packaging cell line referred to as Phoenix 
were used. Phoenix cells are easy to use where DNA integration and 
virus collection is concerned. Phoenix Cells create retrovirus when the 
retrovirus buds off of the Phoenix cell membrane and into the easily 
accessed cell culture supernatant. 48 hours after the transfection, 
supernatant containing the virus was collected. 
 Next we purified CD8+ T cells from mice. The purification 
process began with the removal of spleens from mice. The removal was 
followed by a disruption. The disruption allowed for the isolation of 
white blood cells (B cells, T cells, dendritic cells, monocytes, 
macrophages, etc.). The cells were then labeled with an antibody 
cocktail containing biotin-labeled antibodies specific for all white blood 
cell types excluding CD8+ T cells.  
 The white blood cells were then labeled with anti-biotin magnetic 
beads so that they will only bind to cells coated with biotin-labeled 
antibodies (B, CD4 T, DC, macrophages monocytes etc.) again 
excluding the CD8 T cells. Afterwards the cells were placed through a 
magnetic column. Any cells labeled with beads were stuck to the 
magnetic column allowing the unlabeled cells CD8+ T cells to flow 
through. 
 Retrovirus require actively dividing cells in order to be infected, 
therefore we stimulated purified CD8+ T cells with beads coated with 
antibodies specific for CD3 and CD28. CD3 is the major signaling 
component of the T cell receptor and CD28 is the classic secondary 
costimulatory signal that is required for optimal T cell activation which 
results in T cell proliferation. Immediately after T cell purification, the 
CD8 T cells were mixed with these beads along with the cytokine 
interleukin-2 (IL2 ) to activate them. Interleukin- 2 is a T cell growth 
factor required for T cell growth.  
 They day after T cell purification and stimulation (with anti-
CD3/CD28 beads), the T cells are actively dividing. They are mixed in 
with the retroviral supernatant.  Afterwards the retrovirus then infects 
the T cells and the CAR DNA is then stably inserted into the genome of 
T cells. The T cells were monitored and counted on a daily basis after 
this point and constantly fed with more media and IL2 as they continue 
to expand. 
  
 The graph pictured above shows the results garnered when we 
tested one out of twelve of our CAR’s.  Our finding were based on the 
increased expression of CD25.The CAR entitled ABX338 showed an 
increase in CD25 expression where human GCC was concern but did not 
mirror the same affinity for mouse GCC. Our findings have led us to 
believe that further testing is required for a CAR satisfying our 
requirements may lie within the remaining eleven untested CARS. 
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